Novel strategy for three-dimensional fragment-based lead discovery

Journal of Chemical Information and Modeling

Volumn 51, Issue 4, 2011, Pages 959-974

  Yuan, Haoliang ^a   Lu, Tao ^a   Ran, Ting ^a   Liu, Haichun ^a   Lu, Shuai ^a   Tai, Wenting ^a   Leng, Ying ^a   Zhang, Weiwei ^a   Wang, Jian ^a   Chen, Yadong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ENGINEERING; CHEMISTRY;

BINDING MODES; CONFORMATIONAL CHANGE; DRUG TARGETS; FRAGMENT LINKING; NOVEL STRATEGIES; ROOT MEAN SQUARE DEVIATIONS; SPATIAL POSITIONS; TUMOR TARGETS;

BINDING ENERGY;

CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; LIGAND; PROTEIN; SCATTER FACTOR RECEPTOR;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; FACTUAL DATABASE; METABOLISM; MOLECULAR LIBRARY; PROTEIN BINDING; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DATABASES, FACTUAL; DRUG DESIGN; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; SMALL MOLECULE LIBRARIES;

EID: 79955410819     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci200003c     Document Type: Article

References (59)

1. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery Nat. Rev. Drug. Discov. 2004, 3, 660-672 (Pubitemid 39173507)
2. Erlanson, D. A.; Hansen, S. K. Making drugs on proteins: Site-directed ligand discovery for fragment-based lead assembly Curr. Opin. Chem. Biol. 2004, 8, 399-406 (Pubitemid 38993733)
3. Verdonk, M. L.; Hartshorn, M. J. Structure-guided fragment screening for lead discovery Curr. Opin. Drug. Discov. Dev. 2004, 7, 404-410 (Pubitemid 44383546)
4. Zartler, E. R.; Shapiro, M. J. Fragonomics: Fragment-based drug discovery Curr. Opin. Chem. Biol. 2005, 9, 366-370 (Pubitemid 41019682)
5. Boehm, H. J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening J. Med. Chem. 2000, 43, 2664-2674 (Pubitemid 30463915)
6. Shelke, S. V.; Cutting, B.; Jiang, X.; Koliwer-Brandl, H.; Strasser, D. S.; Schwardt, O.; Kelm, S.; Ernst, B. A fragment-based in situ combinatorial approach to identify high-affinity ligands for unknown binding sites Angew. Chem., Int. Ed. 2010, 49, 5721-5725
7. Verlinde, C. L.; Rudenko, G.; Hol, W. G. In search of new lead compounds for trypanosomiasis drug design: A protein structure-based linked-fragment approach J. Comput.-Aided Mol. Des. 1992, 6, 131-147
8. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR Science 1996, 274, 1531-1534 (Pubitemid 26403929)
9. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681 (Pubitemid 40825512)
10. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: Strategic advances and lessons learned Nat. Rev. Drug Discov. 2007, 6, 211-219 (Pubitemid 46344625)
11. Kolb, P.; Caflisch, A. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking J. Med. Chem. 2006, 49, 7384-7392 (Pubitemid 44913398)
12. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931 (Pubitemid 44484938)
13. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP-Retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comput. Sci. 1998, 38, 511-522 (Pubitemid 128594467)
14. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680 (Pubitemid 351956496)
15. Knox, A. J.; Price, T.; Pawlak, M.; Golfis, G.; Flood, C. T.; Fayne, D.; Williams, D. C.; Meegan, M. J.; Lloyd, D. G. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin J. Med. Chem. 2009, 52, 2177-2180
16. Lloyd, D. G.; Golfis, G.; Knox, A. J.; Fayne, D.; Meegan, M. J.; Oprea, T. I. Oncology exploration: Charting cancer medicinal chemistry space Drug Discov. Today 2006, 11, 149-159 (Pubitemid 43375966)
17. Chemical Computing Group. http://www.chemcomp.com (accessed Mar 17, 2010).
18. Lipinski, C. A. Lead- and drug-like compounds: The rule-of-five revolution Drug Discov. Today: Technol. 2004, 1, 337-341 (Pubitemid 40186335)
19. Kontoyianni, M.; McClellan, L. M.; Sokol, G. S. Evaluation of docking performance: Comparative data on docking algorithms J. Med. Chem. 2004, 47, 558-565 (Pubitemid 38129714)
20. Sandor, M.; Kiss, R.; Keseru, G. M. Virtual fragment docking by Glide: A validation study on 190 protein-fragment complexes J. Chem. Inf. Model. 2010, 50, 1165-1172
21. Law, R.; Barker, O.; Barker, J. J.; Hesterkamp, T.; Godemann, R.; Andersen, O.; Fryatt, T.; Courtney, S.; Hallett, D.; Whittaker, M. The multiple roles of computational chemistry in fragment-based drug design J. Comput.-Aided Mol. Des. 2009, 23, 459-473
22. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery Nat. Chem. Biol. 2006, 2, 720-723 (Pubitemid 44764214)
23. Hajduk, P. J. Puzzling through fragment-based drug design Nat. Chem. Biol. 2006, 2, 658-659 (Pubitemid 44764204)
24. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J. M.; Krimm, I. Fragment-based deconstruction of Bcl-xL inhibitors J. Med. Chem. 2010, 53, 2577-2588
25. Jahnke, W.; Florsheimer, A.; Blommers, M. J.; Paris, C. G.; Heim, J.; Nalin, C. M.; Perez, L. B. Second-site NMR screening and linker design Curr. Top. Med. Chem. 2003, 3, 69-80
26. Chen, J.; Zhang, Z.; Stebbins, J. L.; Zhang, X.; Hoffman, R.; Moore, A.; Pellecchia, M. A fragment-based approach for the discovery of isoform-specific p38α inhibitors ACS. Chem. Biol. 2007, 2, 329-336 (Pubitemid 350001581)
27. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: Strategic advances and lessons learned Nat. Rev. Drug Discov. 2007, 6, 211-219 (Pubitemid 46344625)
28. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of inhibitors of protein kinase B using fragment-based lead discovery J. Med. Chem. 2007, 50, 2293-2296 (Pubitemid 46799240)
29. Ciulli, A.; Abell, C. Fragment-based approaches to enzyme inhibition Curr. Opin. Biotechnol. 2007, 18, 489-496
30. Vulpetti, A.; Pevarello, P. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes Curr. Med. Chem. Anticancer Agents 2005, 5, 561-573 (Pubitemid 41158709)
31. D'Alessio, R.; Bargiotti, A.; Metz, S.; Brasca, M. G.; Cameron, A.; Ermoli, A.; Marsiglio, A.; Polucci, P.; Roletto, F.; Tibolla, M.; Vazquez, M. L.; Vulpetti, A.; Pevarello, P. Benzodipyrazoles: A new class of potent CDK2 inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 1315-1319 (Pubitemid 40268983)
32. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50, 409-424 (Pubitemid 46239775)
33. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 Nat. Struct. Biol. 1997, 4, 796-801
34. Kontopidis, G.; McInnes, C.; Pandalaneni, S. R.; McNae, I.; Gibson, D.; Mezna, M.; Thomas, M.; Wood, G.; Wang, S.; Walkinshaw, M. D.; Fischer, P. M. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design Chem. Biol. 2006, 13, 201-211 (Pubitemid 43255592)
35. Richardson, C. M.; Williamson, D. S.; Parratt, M. J.; Borgognoni, J.; Cansfield, A. D.; Dokurno, P.; Francis, G. L.; Howes, R.; Moore, J. D.; Murray, J. B.; Robertson, A.; Surgenor, A. E.; Torrance, C. J. Triazolo[1,5- a ]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SAR Bioorg. Med. Chem. Lett. 2006, 16, 1353-1357 (Pubitemid 43143021)
36. Beattie, J. F.; Breault, G. A.; Ellston, R. P.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: Identification and optimization of substituted 4,6-bis anilino pyrimidines Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960 (Pubitemid 36993619)
37. Breault, G. A.; Ellston, R. P.; Green, S.; James, S. R.; Jewsbury, P. J.; Midgley, C. J.; Pauptit, R. A.; Minshull, C. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: Identification and optimization of substituted 2,4-bis anilino pyrimidines Bioorg. Med. Chem. Lett. 2003, 13, 2961-2966 (Pubitemid 36993620)
38. Anderson, M.; Beattie, J. F.; Breault, G. A.; Breed, J.; Byth, K. F.; Culshaw, J. D.; Ellston, R. P.; Green, S.; Minshull, C. A.; Norman, R. A.; Pauptit, R. A.; Stanway, J.; Thomas, A. P.; Jewsbury, P. J. Imidazo[1,2- a ]pyridines: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation Bioorg. Med. Chem. Lett. 2003, 13, 3021-3026 (Pubitemid 36993629)
39. Liu, J. J.; Dermatakis, A.; Lukacs, C.; Konzelmann, F.; Chen, Y.; Kammlott, U.; Depinto, W.; Yang, H.; Yin, X.; Schutt, A.; Simcox, M. E.; Luk, K. C. 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors Bioorg. Med. Chem. Lett. 2003, 13, 2465-2468 (Pubitemid 36830751)
40. Johnson, L. N.; De Moliner, E.; Brown, N. R.; Song, H.; Barford, D.; Endicott, J. A.; Noble, M. E. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2 Pharmacol. Ther. 2002, 93, 113-124 (Pubitemid 34615553)
41. Moshinsky, D. J.; Bellamacina, C. R.; Boisvert, D. C.; Huang, P.; Hui, T.; Jancarik, J.; Kim, S. H.; Rice, A. G. SU9516: Biochemical analysis of cdk inhibition and crystal structure in complex with cdk2 Biochem. Biophys. Res. Commun. 2003, 310, 1026-1031 (Pubitemid 37188725)
42. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S. Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity J. Med. Chem. 2004, 47, 1662-1675 (Pubitemid 38380910)
43. Luk, K. C.; Simcox, M. E.; Schutt, A.; Rowan, K.; Thompson, T.; Chen, Y.; Kammlott, U.; DePinto, W.; Dunten, P.; Dermatakis, A. A new series of potent oxindole inhibitors of CDK2 Bioorg. Med. Chem. Lett. 2004, 14, 913-917 (Pubitemid 38167614)
44. Byth, K. F.; Cooper, N.; Culshaw, J. D.; Heaton, D. W.; Oakes, S. E.; Minshull, C. A.; Norman, R. A.; Pauptit, R. A.; Tucker, J. A.; Breed, J.; Pannifer, A.; Rowsell, S.; Stanway, J. J.; Valentine, A. L.; Thomas, A. P. Imidazo[1,2- b ]pyridazines: A potent and selective class of cyclin-dependent kinase inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 2249-2252 (Pubitemid 38481399)
45. Pevarello, P.; Brasca, M. G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M. A. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding J. Med. Chem. 2004, 47, 3367-3380 (Pubitemid 38746088)
46. Williamson, D. S.; Parratt, M. J.; Bower, J. F.; Moore, J. D.; Richardson, C. M.; Dokurno, P.; Cansfield, A. D.; Francis, G. L.; Hebdon, R. J.; Howes, R.; Jackson, P. S.; Lockie, A. M.; Murray, J. B.; Nunns, C. L.; Powles, J.; Robertson, A.; Surgenor, A. E.; Torrance, C. J. Structure-guided design of pyrazolo[1,5- a ]pyrimidines as inhibitors of human cyclin-dependent kinase 2 Bioorg. Med. Chem. Lett. 2005, 15, 863-867 (Pubitemid 40467433)
47. Yue, E. W.; DiMeo, S. V.; Higley, C. A.; Markwalder, J. A.; Burton, C. R.; Benfield, P. A.; Grafstrom, R. H.; Cox, S.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C. H.; Trainor, G. L.; Seitz, S. P. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3 Bioorg. Med. Chem. Lett. 2004, 14, 343-346 (Pubitemid 38045119)
48. Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C. H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P. Quinazolines as cyclin dependent kinase inhibitors Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160 (Pubitemid 32406074)
49. Yue, E. W.; Higley, C. A.; DiMeo, S. V.; Carini, D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Burton, C. R.; Cox, S.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.; Boylan, J. F.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C. H.; Seitz, S. P.; Trainor, G. L. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2) J. Med. Chem. 2002, 45, 5233-5248 (Pubitemid 35429163)
50. Pratt, D. J.; Bentley, J.; Jewsbury, P.; Boyle, F. T.; Endicott, J. A.; Noble, M. E. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity J. Med. Chem. 2006, 49, 5470-5477 (Pubitemid 44373179)
51. Richardson, C. M.; Nunns, C. L.; Williamson, D. S.; Parratt, M. J.; Dokurno, P.; Howes, R.; Borgognoni, J.; Drysdale, M. J.; Finch, H.; Hubbard, R. E.; Jackson, P. S.; Kierstan, P.; Lentzen, G.; Moore, J. D.; Murray, J. B.; Simmonite, H.; Surgenor, A. E.; Torrance, C. J. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping Bioorg. Med. Chem. Lett. 2007, 17, 3880-3885 (Pubitemid 46920948)
52. Underiner, T. L.; Herbertz, T.; Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates Anticancer Agents Med. Chem. 2010, 10, 7-27
53. Bellon, S. F.; Kaplan-Lefko, P.; Yang, Y.; Zhang, Y.; Moriguchi, J.; Rex, K.; Johnson, C. W.; Rose, P. E.; Long, A. M.; O'Connor, A. B.; Gu, Y.; Coxon, A.; Kim, T. S.; Tasker, A.; Burgess, T. L.; Dussault, I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations J. Biol. Chem. 2008, 283, 2675-2683
54. Nishii, H.; Chiba, T.; Morikami, K.; Fukami, T. A.; Sakamoto, H.; Ko, K.; Koyano, H. Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1405-1409
55. Christensen, J. G.; Burrows, J.; Salgia, R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett. 2005, 225, 1-26 (Pubitemid 40732764)
56. Boezio, A. A.; Berry, L.; Albrecht, B. K.; Bauer, D.; Bellon, S. F.; Bode, C.; Chen, A.; Choquette, D.; Dussault, I.; Fang, M.; Hirai, S.; Kaplan-Lefko, P.; Larrow, J. F.; Lin, M. H.; Lohman, J.; Potashman, M. H.; Qu, Y.; Rex, K.; Santostefano, M.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Harmange, J. C. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6307-6312
57. Albrecht, B. K.; Harmange, J. C.; Bauer, D.; Berry, L.; Bode, C.; Boezio, A. A.; Chen, A.; Choquette, D.; Dussault, I.; Fridrich, C.; Hirai, S.; Hoffman, D.; Larrow, J. F.; Kaplan-Lefko, P.; Lin, J.; Lohman, J.; Long, A. M.; Moriguchi, J.; O'Connor, A.; Potashman, M. H.; Reese, M.; Rex, K.; Siegmund, A.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S. F. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase J. Med. Chem. 2008, 51, 2879-2882 (Pubitemid 351706015)
58. Porter, J.; Lumb, S.; Franklin, R. J.; Gascon-Simorte, J. M.; Calmiano, M.; Riche, K. L.; Lallemand, B.; Keyaerts, J.; Edwards, H.; Maloney, A.; Delgado, J.; King, L.; Foley, A.; Lecomte, F.; Reuberson, J.; Meier, C.; Batchelor, M. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase Bioorg. Med. Chem. Lett. 2009, 19, 2780-2784
59. Koolman, H.; Heinrich, T.; Bottcher, H.; Rautenberg, W.; Reggelin, M. Syntheses of novel 2,3-diaryl-substituted 5-cyano-4-azaindoles exhibiting c-Met inhibition activity Bioorg. Med. Chem. Lett. 2009, 19, 1879-1882